Difficult-to-Express Proteins Market Size Share and Industry Outlook to 2028

SKU: DM2315 | Last Updated On: Nov 26 2021 | No. of Pages: 180 | Available Formats

> Global Difficult-to-Express Proteins Market Expected to reach a high CAGR by 2028: DataM Intelligence

Global Difficult-to-Express Proteins Market is segmented By Protein (Proteases, Kinases, Membrane Proteins, Others), By Technology (Cell-free Protein Synthesis, Prokaryotic Expression Systems, SUMO Fusion System, Gene Fusion Systems, Others), By Application (Drug Discovery, Protein Purification, Protein Therapeutics, Disease Diagnostics and Monitoring, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2021-2028

Market Overview:

Difficult-to-express proteins are the proteins whose synthesis is difficult in conventional in vivo protein production platforms. Moreover, it is often challenging to express these proteins in heterologous expression systems due to their inherent properties, the tendency to aggregate and form inclusion bodies, intrinsic nature, and difficultly for the foreign host to fold a protein correctly. The special type of proteins such as membrane proteins, antibody types, proteases, kinases, and others are difficult-to-express proteins.

The Global Difficult-to-Express Proteins Market is predicted to reach a high CAGR during the forecast period (2021-2028).

**Source: DataM Intelligence Analysis

Market Dynamics:

The market growth is driven by the rising manufacturing of recombinant proteins for producing complex therapeutics. There is an increase in the research and development activities for the development of difficult-to-express proteins therapeutics due to their properties such as solubility, immunogenicity, and bioactivity when expressed in mammalian cells.

The market is witnessing the development of novel cell-free protein synthesis platforms based on the industrial working horse CHO cells that overcome the issues. For instance, In March 2019, Catalent had launched its next-generation cell line development technology i.e., GPEx Boost to enhance the GPEx expression platform through multiple improvements, including utilization of glutamine synthase (GS) knock-out Chinese hamster ovary (CHO) cell line. The combination of both technology and platform enhancements would result in the cell's improved ability to produce high titers and increase specific protein productivities of interest.

In March 2019, ExcepGed launched Y Combinator with technology that uses an engineered human cell line to produce full-length human proteins for drug discovery. This platform would be used to rapidly express proteins in mammalian cells with the potential to successfully express these larger proteins.

There is an increase in the development of several techniques such as different expression systems, promoters, cultivation media, and condition, chaperone coexpression, solubilization ta, gs, others for producing and purifying difficult-to-express proteins. However, the high cost of systems and difficulty in analyzing target is expected to hinder the market growth.

Covid-19 Impact Analysis:

The pandemic has had a positive impact on the healthcare industry, including the Difficult to Express Protein market. With Several vaccine development and drug discovery campaigns underway the protease segment is has seen massive development. The SARS-CoV-2 main protease is considered a promising drug target, as it is dissimilar to human proteases. The ability to express and purify the proteins in large quantities is critical for the basic research and development of pharmaceutical agents. Covid-19 is expected to positively impact the SUMO fusion synthesis segment. SUMO fusion synthesis had been used in the expression and purification of SARS-CoV. fusion of SUMO to the N-termini of SARS-CoV proteins dramatically enhances expression in Escherichia coli cells.

Market Segmentation:

The difficult-to-express proteins market is segmented based on proteins as proteases, kinases, membrane proteins, and others. Membrane proteins segment account for the significant market share due to the increase in usage of membrane proteins for incorporation into, or binding to, membranes. Transport proteins are essential for the movement of molecules and ions across the membrane. Peripheral membrane proteins act by binding to integral membrane proteins through compatible binding sites. Integral membrane proteins are incorporated into the hydrophobic portion of the lipid bilayer.

The protease segment is expected to have positive market growth due to rising usage of proteases for brewing, tenderization of meat, milk coagulation, digestion, viral and cancer treatment.

**Source: DataM Intelligence Analysis

Further, the market is also classified based on application into technology as cell-free protein synthesis, prokaryotic expression systems, sumo fusion systems, gene fusion systems, and others. Cell-free protein synthesis accounts for a significant market share owing to its advantages in synthesizing difficult-to-express proteins because of its properties such as reaction environment openness and no cell viability constraints. It maximizes active protein production by optimizing the reaction environment with selective positive effectors and eliminating negative effectors.

The prokaryotic expression systems segment accounts for the significant market as it provides a cost-effective, tuneable, and easy operation of a source of recombinant proteins. Companies are introducing new approaches for the production of complex eukaryotic proteins in a prokaryotic expression.

**Source: DataM Intelligence Analysis

Geographical Penetration:

By region, the difficult-to-express proteins market is segmented into North America, South America, Europe, Asia-Pacific, Middle-East, and Africa. Among all of the regions, the North American region dominated the difficult-to-express proteins market due to increasing research and development activities for the development of different technologies for the synthesis of difficult-to-express proteins. Several companies are entering into collaborations with other companies, organizations, and institutes for developing products related to difficult-to-express proteins. It is further expected that the North American region would maintain its dominant position over the forecasted period.

Europe is expected to have a significant market share owing to the increasing investment from government and non-government organizations. The growing prevalence of chronic disease shall stimulate market growth. Chronic diseases are the leading cause of mortality and morbidity in European Countries. The burden of developing chronic diseases such as cardiovascular disease, diabetes, asthma, chronic obstructive pulmonary disease (COPD), HIV/AIDS, mental disorder, and others increases aging populations. According to Eurostat, the age group of aged 65 and more accounts for one-fifth, i.e., 19 % of the European population.

Asia Pacific region is expected to have positive market growth due to increasing the number of several pharmaceutical and biotechnology companies developing therapeutics and technologies related to difficult-to-express proteins. There is an increase in the adoption of novel technologies for the synthesis of difficult-to-express proteins. The rising awareness regarding the novel technologies shall stimulate market growth over the forecasted period.

**Source: DataM Intelligence Analysis

Competitive Landscape:

The difficult-to-express proteins market is highly competitive with product diversification, revenue generation, and opportunities. Several local and international players are present in the market. R&D Systems, Bio-Rad Laboratories, Enzo Life Sciences, Sino Biological, Thermo Fisher Scientific, StressMarq Biosciences, and Lucigen are the leading market players with significant market share.

Companies are focusing on new product launches, technological advancement, product diversification, market expansion, and market penetration strategies for strengthening their position in the market. They are conducting research and development activities for developing difficult-to-express proteins with innovation and diversification. For instance, In May 2019, Catalent had launched its new OneBio Suite for the integrated development, manufacturing, and clinical supply of biologics. One Bio would help in addressing the challenges facing biologic development companies that are looking to accelerate programs to clinic or market, or that require greater simplicity in the development process, including fewer internal resource needs and a reduced risk of rework.

The companies are entering into collaborations, mergers, licensing agreements, strategic partnerships, and acquisitions to increase the demand for difficult-to-express proteins and their expansion across the globe. For instance, in April 2019, Calixar had entered into an exclusive licensing deal with Regeneron. Calyx had provided Regeneron exclusive rights to its technology and expertise. Calixar’s technology platform would allow the company to isolate the full length and pure to highly pure membrane proteins while keeping their structure and function intact. The types of membrane proteins include GPCRs, ion channels, transporters, receptors, and viral proteins.

Lonza America had acquired exclusive rights to Transposagen’s proprietary gene integration technology for the production of therapeutic proteins. Transposagen’s gene integration technology would enable the efficient production of high-titer cell lines that provides the rapid and economical production of complex biological molecules. In September 2017, Airway Therapeutics entered into an exclusive licensing agreement with Glycotope GmbH [Glycotope]. Under the terms of this agreement, Airway had received the worldwide commercial rights to use Glycotope’s proprietary cell line technology, GlycoExpress [GEX], to produce AT-100 (rhSP-D). The GlycoExpress would accelerate the development and large-scale manufacturing of a wide range of biologics, including antibodies and difficult-to-express proteins.

Companies are also raising the funding and investment for increasing their market presence across the globe. For instance, in March 2019, Algenex had raised the funding of Euros 4 million for the production of recombinant biologics. The company would use the scale-up of its proprietary CrisBio baculovirus-expression platform ahead of an anticipated submission to the European Medicines Agency (EMA) of a CrisBio-based minor species vaccine. It would further the commercial rollout of its TopBac system, a plug-and-play patented technology that increases existing baculovirus systems' productivity.

Bio-Rad Laboratories:

Bio-Rad Laboratories, Inc. is an American developer and manufacturer of specialized technological products for the life science research and clinical diagnostics markets established in 1952. Bio-Rad has a worldwide presence with more than 8000 employees and direct channels in 35 different countries outside the U.S.

Product Portfolio of Bio-Rad Laboratories:

  • Digital Biology
  • Genomics
  • Quality Controls
  • Clinical Diagnostics
  • Protein Quantitation and Purification
  • Cell Biology
  • Food Safety
  • Science Education

Key Developments:

  • April 2020, Bio-Rad announced that it has acquired Celsee, Inc., a company that offers instruments and consumables for the isolation, detection, and analysis of single cells. Celsee's Genesis System offers a practical, scalable, and efficient approach to accurately analyze single cells.
  • In November 2019, The ProteinChip SELDI system starter kit has been redesigned to deliver a step-by-step focused introduction to ProteinChip SELDI technology. A kit is a training tool that includes a video tutorial and the ProteinChip arrays, buffer, and reagents needed to generate and evaluate protein profiles from the included human serum and E. coli samples.

Why Purchase the Report:

  • Visualize the composition of the Difficult-to-Express Proteins market products across each indication, highlighting the critical commercial assets and play in terms of technology and applications.
  • Identify commercial opportunities in the Difficult-to-Express Proteins market by analyzing trends and co-development deals.
  • Excel data sheet with thousands of data points of Difficult-to-Express Proteins market-level 4/5 segmentation.
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.

**The Difficult-to-Express Proteins report will provide access to approximately 53 market data tables, 44 figures, and 178 pages

Target Audience:

  • Industry Investors/Investment Bankers
  • Suppliers/Buyers
  • Education & Research Institutes
  • Manufacturers
  • Research Professionals
  • Emerging Companies
  • Distributors

Trending Topics

Soy Protein Market

Pea Protein Market

Table of Contents 

  1. Global Difficult to Express Protein Market -Scope and Methodology

    1. Research Methodology
    2. Scope of the Market
  2. Global Difficult to Express Protein Market -Key Trends and Developments

  3. Global Difficult to Express Protein Market – Executive Summary

    1. Market Snippet by Protein
    2. Market Snippet by Technology
    3. Market Snippet by Application
    4. Market Snippet by Region
  4. Global Difficult to Express Protein Market-Market Dynamics

    1. Market impacting factors
    2. Drivers
    3. Restraints
    4. Opportunities
    5. Impact analysis
  5. Global Difficult to Express Protein Market – Industry Analysis

    1. Porter's five forces analysis
    2. Value chain analysis
    3. Pricing analysis
    4. Patent Analysis
    5. Regulatory Analysis
  6. Global Difficult to Express Protein Market – Covid-19 Impact Analysis

    1. Analysis of COVID-19 on the Market
      1. Before COVID-19 Market Scenario
      2. Present COVID-19 Market Scenario
      3. After COVID-19 or Future Scenario
    2. Pricing Dynamics Amid Covid-19
    3. Demand-Supply Spectrum
    4. Government Initiatives Related to the Market During Pandemic
    5. Manufacturers Strategic Initiatives
  7. Global Difficult to Express Protein Market – By Protein

    1. Introduction
      1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Protein
      2. Market Attractiveness Index, By Protein
    2. Proteases
    3. Kinases
    4. Membrane Proteins
    5. Others
  8. Global Difficult to Express Protein Market – By Technology

    1. Introduction
      1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
      2. Market Attractiveness Index, By Technology
    2. Cell-free Protein Synthesis
    3. Prokaryotic Expression Systems
    4. SUMO Fusion System
    5. Gene Fusion Systems
    6. Others
  9. Global Difficult to Express Protein Market – By Application

    1. Introduction
      1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
      2. Market Attractiveness Index, By Application
    2. Drug Discovery
    3. Protein Purification
    4. Protein Therapeutics
    5. Disease Diagnostics and Monitoring
    6. Others
       
  10. Global Difficult to Express Protein Market – By Region

    1. Introduction
      1. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Region
      2. Market Attractiveness Index, By Region
    2. North America
      1. Introduction
      2. Key region-specific dynamics
      3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Type
      4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Technology
      5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Feed Type
      6. Market Size Analysis, And Y-O-Y Growth Analysis (%), By End User
      7. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
        1. U.S.
        2. Canada
        3. Mexico
    3. Europe
      1. Introduction
      2. Key Region-Specific Dynamics
      3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Type
      4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Technology
      5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Feed Type
      6. Market Size Analysis, And Y-O-Y Growth Analysis (%), By End User
      7. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
        1. Germany
        2. U.K.
        3. France
        4. Italy
        5. Spain
        6. Rest of Europe
    4. South America
      1. Introduction
      2. Key Region-Specific Dynamics
      3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Type
      4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Technology
      5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Feed Type
      6. Market Size Analysis, And Y-O-Y Growth Analysis (%), By End User
      7. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
        1. Brazil
        2. Argentina
        3. Chile
        4. Rest of South America
    5. Asia Pacific
      1. Introduction
      2. Key Region-Specific Dynamics
      3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Type
      4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Technology
      5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Feed Type
      6. Market Size Analysis, And Y-O-Y Growth Analysis (%), By End User
      7. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
        1. China
        2. India
        3. Japan
        4. Australia & New Zealand
        5. Rest of Asia Pacific
    6. The Middle East and Africa
      1. Introduction
      2. Key Region-Specific Dynamics
      3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Type
      4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Technology
      5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Feed Type
      6. Market Size Analysis, And Y-O-Y Growth Analysis (%), By End User
  11. Global Difficult to Express Protein Market – Competitive Landscape

    1. Competitive scenario
    2. Competitor strategy analysis
    3. Comparative analysis
    4. Market positioning/share analysis
    5. Mergers and acquisitions analysis
  12. Global Difficult to Express Protein Market – Company Profiles

    1. Bio-Rad Laboratories
      1. Company Overview
      2. Form Portfolio and Description
      3. Key Highlights
      4. Financial Overview
    2. R&D Systems
    3. Enzo Life Sciences
    4. Sino Biological
    5. Thermo Fisher Scientific
    6. StressMarq Biosciences
    7. LifeSensors
    8. Lucigen
    9. Origene
    10. Biolegend
  13. Global Difficult to Express Protein Market – Premium Insights

  14. Global Difficult to Express Protein Market – DataM

    1. Appendix
    2. About us and services
    3. Contact us

List of Tables & Figures

List of Tables

Table 01 Difficult-to-Express Proteins Market Value, By Protein, 2020,2024 & 2028 ($ Million)

Table 02 Difficult-to-Express Proteins Market Value, By Technology, 2020,2024 & 2028 ($ Million)

Table 03 Difficult-to-Express Proteins Market Value, By Application, 2020,2024 & 2028 ($ Million)

Table 04 Difficult-to-Express Proteins Market Value, By Region, 2020,2024 & 2028 ($ Million)

Table 05 Difficult-to-Express Proteins Market Value, By Protein, 2020,2024 & 2028 ($ Million)

Table 06 Difficult-to-Express Proteins Market Value, By Protein, 2020-2028 ($ Million)

Table 07 Difficult-to-Express Proteins Market Value, By Technology, 2020,2024 & 2028 ($ Million)

Table 08 Difficult-to-Express Proteins Market Value, By Technology, 2020-2028 ($ Million)

Table 09 Difficult-to-Express Proteins Market Value, By Application, 2020,2024 & 2028 ($ Million)

Table 10 Difficult-to-Express Proteins Market Value, By Application, 2020-2028 ($ Million)

Table 11 Difficult-to-Express Proteins Market Value, By Region, 2020,2024 & 2028 ($ Million)

Table 12 Difficult-to-Express Proteins Market Value, By Region, 2020-2028 ($ Million)

Table 13 North America Difficult-to-Express Proteins Market Value, By Protein, 2020-2028 ($ Million)

Table 14 North America Difficult-to-Express Proteins Market Value, By Technology, 2020-2028 ($ Million)

Table 15 North America Difficult-to-Express Proteins Market Value, By Application, 2020-2028 ($ Million)

Table 16 North America Difficult-to-Express Proteins Market Value, By Country, 2020-2028 ($ Million)

Table 17 South America Difficult-to-Express Proteins Market Value, By Protein, 2020-2028 ($ Million)

Table 18 South America Difficult-to-Express Proteins Market Value, By Technology, 2020-2028 ($ Million)

Table 19 South America Difficult-to-Express Proteins Market Value, By Application, 2020-2028 ($ Million)

Table 20 South America Difficult-to-Express Proteins Market Value, By Country, 2020-2028 ($ Million)

Table 21 Europe Difficult-to-Express Proteins Market Value, By Protein, 2020-2028 ($ Million)

Table 22 Europe Difficult-to-Express Proteins Market Value, By Technology, 2020-2028 ($ Million)

Table 23 Europe Difficult-to-Express Proteins Market Value, By Application, 2020-2028 ($ Million)

Table 24 Europe Difficult-to-Express Proteins Market Value, By Country, 2020-2028 ($ Million)

Table 25 Asia-Pacific Difficult-to-Express Proteins Market Value, By Protein, 2020-2028 ($ Million)

Table 26 Asia-Pacific Difficult-to-Express Proteins Market Value, By Technology, 2020-2028 ($ Million)

Table 27 Asia-Pacific Difficult-to-Express Proteins Market Value, By Application, 2020-2028 ($ Million)

Table 28 Asia-Pacific Difficult-to-Express Proteins Market Value, By Country, 2020-2028 ($ Million)

Table 29 the Middle East & Africa Difficult-to-Express Proteins Market Value, By Protein, 2020-2028 ($ Million)

Table 30 the Middle East & Africa Difficult-to-Express Proteins Market Value, By Technology, 2020-2028 ($ Million)

Table 31 the Middle East & Africa Difficult-to-Express Proteins Market Value, By Application, 2020-2028 ($ Million)

Table 32 Bio-Rad Laboratories: Overview

Table 33 Bio-Rad Laboratories: Product Portfolio

Table 34 Bio-Rad Laboratories: Key Developments

Table 35 R&D Systems: Overview

Table 36 R&D Systems: Product Portfolio

Table 37 R&D Systems: Key Developments

Table 38 Enzo Life Sciences: Overview

Table 39 Enzo Life Sciences: Product Portfolio

Table 40 Enzo Life Sciences: Key Developments

Table 41 Sino Biological: Overview

Table 42 Sino Biological: Product Portfolio

Table 43 Sino Biological: Key Developments

Table 44 Thermo Fisher Scientific: Overview

Table 45 Thermo Fisher Scientific: Product Portfolio

Table 46 Thermo Fisher Scientific: Key Developments

Table 47 StressMarq Biosciences: Overview

Table 48 StressMarq Biosciences: Product Portfolio

Table 49 StressMarq Biosciences: Key Developments

Table 50 LifeSensors: Overview

Table 51 LifeSensors: Product Portfolio

Table 52 LifeSensors: Key Developments

Table 53 Lucigen: Overview

Table 54 Lucigen: Product Portfolio

Table 55 Lucigen: Key Developments

Table 56 Origene: Overview

Table 57 Origene: Product Portfolio

Table 58 Origene: Key Developments

Table 59 Biolegend: Overview

Table 60 Biolegend: Product Portfolio

Table 61 Biolegend: Key Developments

List of Figures

Figure 01 Difficult-to-Express Proteins Market Share, By Protein, 2020 & 2028 (%)

Figure 02 Difficult-to-Express Proteins Market Share, By Technology, 2020 & 2028 (%)

Figure 03 Difficult-to-Express Proteins Market Share, By Application, 2020 & 2028 (%)

Figure 04 Difficult-to-Express Proteins Market Share, By Region, 2020 & 2028 (%)

Figure 05 Difficult-to-Express Proteins Market Value, 2020-2028 ($ Million)

Figure 06 Difficult-to-Express Proteins Market Y-o-Y Growth, By Protein, 2020-2028 (%)

Figure 07 Proteases: Difficult-to-Express Proteins Market Value, 2020-2028 ($ Million)

Figure 08 Kinases: Difficult-to-Express Proteins Market Value, 2020-2028 ($ Million)

Figure 09 Membrane Proteins: Difficult-to-Express Proteins Market Value, 2020-2028 ($ Million)

Figure 10 Others: Difficult-to-Express Proteins Market Value, 2020-2028 ($ Million)

Figure 11 Difficult-to-Express Proteins Market Y-o-Y Growth, By Technology, 2020-2028 (%)

Figure 12 Cell-free Protein Synthesis: Difficult-to-Express Proteins Market Value, 2020-2028 ($ Million)

Figure 13 SUMO Fusion System: Difficult-to-Express Proteins Market Value, 2020-2028 ($ Million)

Figure 14 Gene Fusion Systems: Difficult-to-Express Proteins Market Value, 2020-2028 ($ Million)

Figure 15 Others: Difficult-to-Express Proteins Market Value, 2020-2028 ($ Million)

Figure 16 Difficult-to-Express Proteins Market Y-o-Y Growth, By Application, 2020-2028 (%)

Figure 17 Drug Discovery: Difficult-to-Express Proteins Market Value, 2020-2028 ($ Million)

Figure 18 Protein Purification: Difficult-to-Express Proteins Market Value, 2020-2028 ($ Million)

Figure 19 Protein Therapeutics: Difficult-to-Express Proteins Market Value, 2020-2028 ($ Million)

Figure 20 Disease Diagnostics and Monitoring: Difficult-to-Express Proteins Market Value, 2020-2028 ($ Million)

Figure 21 Others: Difficult-to-Express Proteins Market Value, 2020-2028 ($ Million)

Figure 22 Difficult-to-Express Proteins Market Y-o-Y Growth, By Region, 2020-2028 (%)

Figure 23 North America Difficult-to-Express Proteins Market Value, 2020-2028 ($ Million)

Figure 24 North America Difficult-to-Express Proteins Market Share, By Protein, 2020 & 2028 (%)

Figure 25 North America Difficult-to-Express Proteins Market Share, By Technology, 2020 & 2028 (%)

Figure 26 North America Difficult-to-Express Proteins Market Share, By Application, 2020 & 2028 (%)

Figure 27 North America Difficult-to-Express Proteins Market Share, By Country, 2020 & 2028 (%)

Figure 28 South America Difficult-to-Express Proteins Market Value, 2020-2028 ($ Million)

Figure 29 South America Difficult-to-Express Proteins Market Share, By Protein, 2020 & 2028 (%)

Figure 30 South America Difficult-to-Express Proteins Market Share, By Technology, 2020 & 2028 (%)

Figure 31 South America Difficult-to-Express Proteins Market Share, By Application, 2020 & 2028 (%)

Figure 32 South America Difficult-to-Express Proteins Market Share, By Country, 2020 & 2028 (%)

Figure 33 Europe Difficult-to-Express Proteins Market Value, 2020-2028 ($ Million)

Figure 34 Europe Difficult-to-Express Proteins Market Share, By Protein, 2020 & 2028 (%)

Figure 45 Europe Difficult-to-Express Proteins Market Share, By Technology, 2020 & 2028 (%)

Figure 36 Europe Difficult-to-Express Proteins Market Share, By Application, 2020 & 2028 (%)

Figure 37 Europe Difficult-to-Express Proteins Market Share, By Country, 2020 & 2028 (%)

Figure 38 Asia-Pacific Difficult-to-Express Proteins Market Value, 2020-2028 ($ Million)

Figure 39 Asia-Pacific Difficult-to-Express Proteins Market Share, By Protein, 2020 & 2028 (%)

Figure 40 Asia-Pacific Difficult-to-Express Proteins Market Share, By Technology, 2020 & 2028 (%)

Figure 41 Asia-Pacific Difficult-to-Express Proteins Market Share, By Application, 2020 & 2028 (%)

Figure 42 Asia-Pacific Difficult-to-Express Proteins Market Share, By Country, 2020 & 2028 (%)

Figure 43 Middle East & Africa Difficult-to-Express Proteins Market Value, 2020-2028 ($ Million)

Figure 44 Middle East & Africa Difficult-to-Express Proteins Market Share, By Protein, 2020 & 2028 (%)

Figure 45 Middle East & Africa Difficult-to-Express Proteins Market Share, By Technology, 2020 & 2028 (%)

Figure 46 Middle East & Africa Difficult-to-Express Proteins Market Share, By Application, 2020 & 2028 (%)

Figure 47 Bio-Rad Laboratories: Financials

Figure 48 R&D Systems: Financials

Figure 49 Enzo Life Sciences: Financials

Figure 50 Sino Biological: Financials

Figure 51 Thermo Fisher Scientific: Financials

Figure 52 LifeSensors: Financials

Figure 53       StressMarq Biosciences: Financials

Figure 54 LifeSensors: Financials

Figure 55 Origene: Financials

Figure 56 Biolegend: Financials

Did not find what you were looking for?Every 7 out of 10 customers request tailored reports. Get yours today!
We collate your requirements.
Our global research team is put into action.
We deliver, and make sure your endeavour is a success!

Buy This Report

20% Discount Applied*



Year-End Offer from
DataM Intelligence

Note*: For "Bundle/Bulk" Subscription of Reports,
please contact: [email protected]

Get your free sample proposal with a single click!

linkedinpinterest